31 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
1 study for both indications.
We expect topline data from the Phase 1 study with CDI-988 in 2024.
2023 Financial Results
Research and development (R … &D) expenses for 2023 were $15.2 million, compared with $12.4 million for 2022. The increase was primarily due to advancing influenza candidate CC
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
-coronavirus oral CDI-988 Phase 1 trial.
Third Quarter Financial Results
Research and development (R&D) expenses for the third quarter of 2023 were $4.2 … , or $0.70 per share.
Nine Month Financial Results
R&D expenses for the nine months ended September 30, 2023 were $10.9 million, compared with $9.1
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
, who currently is Chairman and CEO of OPKO Health.
Second Quarter Financial Results
Research and development (R&D) expenses for the second quarter … of $19.1 million.
Six Month Financial Results
R&D expenses for the six months ended June 30, 2023 were $6.7 million, compared with $5.2 million
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
clinical trial with CDI-988 for COVID-19, and advancing the preclinical norovirus program, partially offset by a reduction in R&D tax credits. General
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
million people worldwide have chronic HCV infections.
Second Quarter 2022 Financial Results
Research and development (R&D) expenses for the second … transitioning from the preclinical discovery stage into a clinical trial. The Company is anticipating increased R&D expenses during the second half
8-K
EX-99.1
10jr48c236j6f7 dlxa
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
w9pj4cjiyi
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
1vckfriu6
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-99.1
3rnpso8y4s814gjq0euw
7 Jan 19
Cocrystal Pharma Announces Exclusive Worldwide License and Collaboration Agreement with Merck
9:03am